Receptor tyrosine kinases in cancer escape from BRAF inhibitors

Por Lo, Roger S
Publicado em 2012

Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas

Por Lo, Roger S
Publicado em 2012

Evolution of resistance to MAPK-targeted therapies

Por Lo, Roger
Publicado no J Transl Med (2015)

Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor TGIF

Por Lo, Roger S., Wotton, David, Massagué, Joan
Publicado em 2001

Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to (V600E)B-RAF inhibition

Por Shi, Hubing, Kong, Xiangju, Ribas, Antoni, Lo, Roger s.
Publicado em 2011

Determinants of specificity in TGF-β signal transduction

Por Chen, Ye-Guang, Hata, Akiko, Lo, Roger S., Wotton, David, Shi, Yigong, Pavletich, Nikola, Massagué, Joan
Publicado em 1998

Therapy-induced tumour secretomes promote resistance and tumour progression

Por Obenauf, Anna C., Zou, Yilong, Ji, Andrew L., Vanharanta, Sakari, Shu, Weiping, Shi, Hubing, Kong, Xiangju, Bosenberg, Marcus C., Wiesner, Thomas, Rosen, Neal, Lo, Roger S., Massagué, Joan
Publicado no Nature (2015)

Vemurafenib resistance reprograms melanoma cells towards glutamine dependence

Por Hernandez-Davies, Jenny E, Tran, Thai Q, Reid, Michael A, Rosales, Kimberly R, Lowman, Xazmin H, Pan, Min, Moriceau, Gatien, Yang, Ying, Wu, Jun, Lo, Roger S, Kong, Mei
Publicado no J Transl Med (2015)

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

Por Atefi, Mohammad, von Euw, Erika, Attar, Narsis, Ng, Charles, Chu, Connie, Guo, Deliang, Nazarian, Ramin, Chmielowski, Bartosz, Glaspy, John A., Comin-Anduix, Begonya, Mischel, Paul S., Lo, Roger S., Ribas, Antoni
Publicado em 2011

Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations

Por Niehr, Franziska, von Euw, Erika, Attar, Narsis, Guo, Deliang, Matsunaga, Doug, Sazegar, Hooman, Ng, Charles, Glaspy, John A, Recio, Juan A, Lo, Roger S, Mischel, Paul S, Comin-Anduix, Begonya, Ribas, Antoni
Publicado em 2011

Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death

Por Graham, Nicholas A, Tahmasian, Martik, Kohli, Bitika, Komisopoulou, Evangelia, Zhu, Maggie, Vivanco, Igor, Teitell, Michael A, Wu, Hong, Ribas, Antoni, Lo, Roger S, Mellinghoff, Ingo K, Mischel, Paul S, Graeber, Thomas G
Publicado em 2012

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

Por Hugo, Willy, Shi, Hubing, Sun, Lu, Piva, Marco, Song, ChunYing, Kong, Xiangju, Moriceau, Gatien, Hong, Aayoung, Dahlman, Kimberly B., Johnson, Douglas B., Sosman, Jeffrey A., Ribas, Antoni, Lo, Roger S.
Publicado no Cell (2015)

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Por Wong, Deborah JL, Robert, Lidia, Atefi, Mohammad S, Lassen, Amanda, Avarappatt, Geetha, Cerniglia, Michael, Avramis, Earl, Tsoi, Jennifer, Foulad, David, Graeber, Thomas G, Comin-Anduix, Begonya, Samatar, Ahmed, Lo, Roger S, Ribas, Antoni
Publicado em 2014

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Por Wong, Deborah JL, Robert, Lidia, Atefi, Mohammad S, Lassen, Amanda, Avarappatt, Geetha, Cerniglia, Michael, Avramis, Earl, Tsoi, Jennifer, Foulad, David, Graeber, Thomas G, Comin-Anduix, Begonya, Samatar, Ahmed, Lo, Roger S, Ribas, Antoni
Publicado no Mol Cancer (2015)

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition

Por Shi, Hubing, Hong, Aayoung, Kong, Xiangju, Koya, Richard C., Song, Chunying, Moriceau, Gatien, Hugo, Willy, Yu, Clarissa C., Ng, Charles, Chodon, Thinle, Scolyer, Richard A., Kefford, Richard F., Ribas, Antoni, Long, Georgina V., Lo, Roger S.
Publicado em 2013

Preexisting MEK1 Exon 3 Mutations in (V600E/K)BRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors

Por Shi, Hubing, Moriceau, Gatien, Kong, Xiangju, Koya, Richard C., Nazarian, Ramin, Pupo, Gulietta M., Bacchiocchi, Antonella, Dahlman, Kimberly B., Chmielowski, Bartosz, Sosman, Jeffrey A., Halaban, Ruth, Kefford, Richard F., Long, Georgina V., Ribas, Antoni, Lo, Roger S.
Publicado em 2012

COX‐2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors

Por Escuin-Ordinas, Helena, Atefi, Mohammad, Fu, Yong, Cass, Ashley, Ng, Charles, Huang, Rong Rong, Yashar, Sharona, Comin-Anduix, Begonya, Avramis, Earl, Cochran, Alistair J., Marais, Richard, Lo, Roger S., Graeber, Thomas G., Herschman, Harvey R., Ribas, Antoni
Publicado em 2013

JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma

Por Titz, Bjoern, Lomova, Anastasia, Le, Allison, Hugo, Willy, Kong, Xiangju, ten Hoeve, Johanna, Friedman, Michael, Shi, Hubing, Moriceau, Gatien, Song, Chunying, Hong, Aayoung, Atefi, Mohammad, Li, Richard, Komisopoulou, Evangelia, Ribas, Antoni, Lo, Roger S, Graeber, Thomas G
Publicado no Cell Discov (2016)

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Por Nazarian, Ramin, Shi, Hubing, Wang, Qi, Kong, Xiangju, Koya, Richard C., Lee, Hane, Chen, Zugen, Lee, Mi-Kyung, Attar, Narsis, Sazegar, Hooman, Chodon, Thinle, Nelson, Stanley F., McArthur, Grant, Sosman, Jeffrey A., Ribas, Antoni, Lo, Roger S.
Publicado em 2010

The heat shock protein-90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms

Por Paraiso, Kim H. T., Haarberg, H. Eirik, Wood, Elizabeth, Rebecca, Vito W., Chen, Y. Ann, Xiang, Yun, Ribas, Antoni, Lo, Roger S., Weber, Jeffrey S., Sondak, Vernon K., John, Jobin K., Sarnaik, Amod A., Koomen, John M., Smalley, Keiran S. M.
Publicado em 2012